Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H13As2N2O4S.Na |
Molecular Weight | 466.151 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].NC1=CC(=CC=C1O)\[As]=[As]\C2=CC=C(O)C(NCOS[O-])=C2
InChI
InChIKey=CXFGBOZIEIIEIH-UHFFFAOYSA-M
InChI=1S/C13H14As2N2O4S.Na/c16-10-5-8(1-3-12(10)18)14-15-9-2-4-13(19)11(6-9)17-7-21-22-20;/h1-6,17-20H,7,16H2;/q;+1/p-1
Neoarsphenamine and related compounds are sulfhydryl-binding agents which are tolerated by man. A large experience in the employment of this drug and its toxic manifestations exists as a result of its former use as an antisyphilitic agent. Tertiary syphilis was a common cause for mental health conditions. Also known as Neosalvarsan, it superseded Salvarsan due to its lower toxicity. Both arsenicals still carried significant risk of side-effects and were themselves replaced by penicillin in the 1940s. Neoarsphenamine was also used for the treatment of amebic dysentery.
Approval Year
Sample Use Guides
Intravenous injections of 0.3 g in the treatment of urinary tract infections and gonorrheal prostatitis
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4225867
A buffered saline suspension containing approximately 2.5 x 10(7) cells/ml of M. sodonensis was made from a culture growing in log phase. The suspension was divided in half. To one portion neoarsphenamine was added to a concentration of 10(−3) M.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
457-60-3
Created by
admin on Fri Dec 15 15:10:04 GMT 2023 , Edited by admin on Fri Dec 15 15:10:04 GMT 2023
|
PRIMARY | |||
|
400
Created by
admin on Fri Dec 15 15:10:04 GMT 2023 , Edited by admin on Fri Dec 15 15:10:04 GMT 2023
|
PRIMARY | |||
|
C073331
Created by
admin on Fri Dec 15 15:10:04 GMT 2023 , Edited by admin on Fri Dec 15 15:10:04 GMT 2023
|
PRIMARY | |||
|
207-273-7
Created by
admin on Fri Dec 15 15:10:04 GMT 2023 , Edited by admin on Fri Dec 15 15:10:04 GMT 2023
|
PRIMARY | |||
|
m7802
Created by
admin on Fri Dec 15 15:10:04 GMT 2023 , Edited by admin on Fri Dec 15 15:10:04 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID60196599
Created by
admin on Fri Dec 15 15:10:04 GMT 2023 , Edited by admin on Fri Dec 15 15:10:04 GMT 2023
|
PRIMARY | |||
|
SUB09193MIG
Created by
admin on Fri Dec 15 15:10:04 GMT 2023 , Edited by admin on Fri Dec 15 15:10:04 GMT 2023
|
PRIMARY | |||
|
O7K7R0O4BG
Created by
admin on Fri Dec 15 15:10:04 GMT 2023 , Edited by admin on Fri Dec 15 15:10:04 GMT 2023
|
PRIMARY | |||
|
NEOSALVARSAN
Created by
admin on Fri Dec 15 15:10:04 GMT 2023 , Edited by admin on Fri Dec 15 15:10:04 GMT 2023
|
PRIMARY | |||
|
C174787
Created by
admin on Fri Dec 15 15:10:04 GMT 2023 , Edited by admin on Fri Dec 15 15:10:04 GMT 2023
|
PRIMARY | |||
|
76961391
Created by
admin on Fri Dec 15 15:10:04 GMT 2023 , Edited by admin on Fri Dec 15 15:10:04 GMT 2023
|
PRIMARY | |||
|
100000084152
Created by
admin on Fri Dec 15 15:10:04 GMT 2023 , Edited by admin on Fri Dec 15 15:10:04 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD